Nature Communications (Jun 2019)
Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations
Abstract
The BCL-2 mutation G101V reduces venetoclax affinity and confers drug resistance in patients with chronic lymphocytic leukaemia. Here, the authors present crystal structures and biochemical analyses of venetoclax bound to BCL-2 and the G101V mutant, revealing the structural basis for venetoclax resistance.